Consensus statement on the management of incidentally discovered FDG avid thyroid nodules in patients being investigated for other cancers.
Jonathan WadsleySabapathy P BalasubramanianGitta MadaniJean MundayTom RoquesChristopher W RowePhilip TouskaKristien BoelaertPublished in: Clinical endocrinology (2023)
With the widespread use of 18F-fluorodeoxyglucose positron emission tomography (FDG PET/CT) in the investigation and staging of cancers, incidental discovery of FDG-avid thyroid nodules is becoming increasingly common, with a reported incidence in the range 1%-4% of FDG PET/CT scans. The risk of malignancy in an incidentally discovered FDG avid thyroid nodule is not clear due to selection bias in reported retrospective series but is likely to be less than 15%. Even in cases where the nodule is found to be malignant, the majority will be differentiated thyroid cancers with an excellent prognosis even without treatment. If, due to index cancer diagnosis, age and co-morbidities, it is unlikely that the patient will survive 5 years, further investigation of an incidental FDG avid thyroid nodule is unlikely to be warranted. We provide a consensus statement on the circumstances in which further investigation of FDG avid thyroid nodules with ultrasound and fine needle aspiration might be appropriate.
Keyphrases
- positron emission tomography
- computed tomography
- pet ct
- pet imaging
- fine needle aspiration
- magnetic resonance imaging
- ultrasound guided
- ejection fraction
- newly diagnosed
- small molecule
- contrast enhanced
- magnetic resonance
- squamous cell carcinoma
- mass spectrometry
- atomic force microscopy
- patient reported outcomes
- high resolution
- smoking cessation